Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nika Pharmaceuticals Inc. (NIKA)
Henderson, NV, US
Nika Pharmaceuticals Inc., a pharmaceutical enterprise headquartered in Henderson, Nevada, focuses on the creation of medications to address a broad spectrum of health conditions. Its research and development efforts target serious diseases including HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, and diabetes. The company's product line features antiviral treatments and nutritional supplements, notably providing a specialized thymus nuclear glycoprotein for the management of HIV. Originally established in 2000, the organization was previously known as Centennial Growth Equities Inc. before adopting its current name, Nika Pharmaceuticals, Inc., in May 2022.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -60.39% | -49.75% | -73.26% | -19.20% | -46.86% | -68.92% | +1.00% | +1.00% | +1.00% | +1.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-03 |
|---|---|
| Strong Buy | 0 |
| Buy | 0 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+0.0%
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'26: +17.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.5% Q1'26: +2.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× Q1'26: 0.00× (vs Q1'25)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Clifford Redekop | Secretary & Director | — | male |
| Dimitar Slavchev Savov | President, Chief Executive Officer, Chief Financial Officer & Director | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NIKA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
